-
1 Comment
IGM Biosciences, Inc is currently in a long term uptrend where the price is trading 7.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
IGM Biosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 99.5% to $-81K since the same quarter in the previous year.
Finally, its free cash flow fell by 132.7% to $-29M since the same quarter in the previous year.
Based on the above factors, IGM Biosciences, Inc gets an overall score of 3/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | US4495851085 |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Market Cap | 431M |
|---|---|
| Target Price | 33.3 |
| PE Ratio | None |
| Dividend Yield | 0.0% |
| Beta | -0.16 |
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IGMS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
